Nafiseh Toghianifar1, Fereshteh Ashtari2, Sayyed Hamid Zarkesh-Esfahani3, Marjan Mansourian4. 1. Isfahan University of Medical Sciences, Isfahan, Iran. Electronic address: n.toghiani@gmail.com. 2. Isfahan University of Medical Sciences, Isfahan, Iran; Isfahan Neuroscience Research Centre, Iran. 3. University of Isfahan, Department of Biology, Isfahan, Iran. 4. Department of Biostatistics and Epidemiology, Health School, Isfahan University of Medical Sciences, Isfahan, Iran.
Abstract
BACKGROUND:Vitamin D has immunomodulatory effects in multiple sclerosis (MS). Vitamin D acts through various mechanisms such as secretion of cytokines. Interleukin-17 (IL-17) is a critical interleukin in inflammatory response in MS. OBJECTIVE: This study assessed the effect of oral high dose vitamin D intake on IL-17 levels in MS patients in a double blind randomized clinical trial. METHODS:94 patients with a diagnosis of relapsing remitting multiple sclerosis (RRMS) were randomized to two groups. One group received 50,000 IU vitamin D3 every five days for 12weeks. The other group was given placebo. Both groups received interferon-β (IFN-β) treatment. Serum levels of IL-17 were measured at the beginning of the study and after 12weeks. RESULTS:IL-17 serum levels were 56.75±28.72pg/ml and 30.31±75.85pg/ml in the intervention and placebo group at the beginning of the study, respectively (Median±IQR, p=0.338). After 12weeks, IL-17 levels were 58.93±67.93pg/ml and 46.13±94.70pg/ml in the intervention and placebo group, respectively (Median±IQR, p=0.960). The multiple linear regression analysis indicated that the consumption of vitamin D3 was positively and significantly associated with the logarithm of IL-17 measures (β=1.719; p=0.002 and R2=0.91), adjusted by EDSS scores. CONCLUSION:IL-17 levels showed significant change in RRMS patients after receiving high dose vitamin D3 for 12weeks.
RCT Entities:
BACKGROUND:Vitamin D has immunomodulatory effects in multiple sclerosis (MS). Vitamin D acts through various mechanisms such as secretion of cytokines. Interleukin-17 (IL-17) is a critical interleukin in inflammatory response in MS. OBJECTIVE: This study assessed the effect of oral high dose vitamin D intake on IL-17 levels in MS patients in a double blind randomized clinical trial. METHODS: 94 patients with a diagnosis of relapsing remitting multiple sclerosis (RRMS) were randomized to two groups. One group received 50,000 IU vitamin D3 every five days for 12weeks. The other group was given placebo. Both groups received interferon-β (IFN-β) treatment. Serum levels of IL-17 were measured at the beginning of the study and after 12weeks. RESULTS:IL-17 serum levels were 56.75±28.72pg/ml and 30.31±75.85pg/ml in the intervention and placebo group at the beginning of the study, respectively (Median±IQR, p=0.338). After 12weeks, IL-17 levels were 58.93±67.93pg/ml and 46.13±94.70pg/ml in the intervention and placebo group, respectively (Median±IQR, p=0.960). The multiple linear regression analysis indicated that the consumption of vitamin D3 was positively and significantly associated with the logarithm of IL-17 measures (β=1.719; p=0.002 and R2=0.91), adjusted by EDSS scores. CONCLUSION:IL-17 levels showed significant change in RRMS patients after receiving high dose vitamin D3 for 12weeks.
Authors: Manuel Zeitelhofer; Milena Z Adzemovic; David Gomez-Cabrero; Petra Bergman; Sonja Hochmeister; Marie N'diaye; Atul Paulson; Sabrina Ruhrmann; Malin Almgren; Jesper N Tegnér; Tomas J Ekström; André Ortlieb Guerreiro-Cacais; Maja Jagodic Journal: Proc Natl Acad Sci U S A Date: 2017-02-14 Impact factor: 11.205
Authors: M José Bagur; M Antonia Murcia; Antonia M Jiménez-Monreal; Josep A Tur; M Mar Bibiloni; Gonzalo L Alonso; Magdalena Martínez-Tomé Journal: Adv Nutr Date: 2017-05-15 Impact factor: 8.701
Authors: Vanitha A Jagannath; Graziella Filippini; Carlo Di Pietrantonj; G V Asokan; Edward W Robak; Liz Whamond; Sarah A Robinson Journal: Cochrane Database Syst Rev Date: 2018-09-24